DFine presented pre-clinical data of Star Tumor Ablation System at WCIO


DFine announced it has presented the poster: “Radiofrequency ablation and vertebral augmentation of bone metastasis of the spine: early experience of a novel minimally-invasive technology” at the World Congress of Interventional Oncology (WCIO) on 14 and 16 June in Chicago, USA. The poster covered the initial pre-clinical and clinical use of the Star Tumor Ablation System using targeted radiofrequency ablation (t-RFA) for the treatment of metastatic vertebral body tumors.

“Our goal is to work closely with the interventional and oncology professional communities to obtain clinical evidence and continually advance our knowledge of the role of t-RFA with the Star system in the palliative treatment of patients with painful vertebral body metastasis,” said Kevin Mosher, CEO, DFine. “Early results have been encouraging, and we are pleased to share this data with the Interventional Oncology Community at WCIO.” 

DFine recently completed the initial phase of its US commercial release of the Star System. According to a company release, more than 50 patients have been treated at 26 centres across the country since the initial product rollout in March 2012.